Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CH0210362643
Wed, 10.09.2025
BioVersys AG
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland. September 10, 2025, 7am CEST
BV100: successful end of Phase 2 meeting with US FDA following Positive Phase 2 read-out in Ventilator-Associated Bacterial Pneumonia (VABP); Phase 3 on track to initiate in 2025; Formulation patent granted in China, extending BV100 [ … ]
Fri, 29.08.2025
BioVersys AG
BioVersys AG
/ Key word(s): Half Year Results
Bioversys To announce its FIrst half 2025 financial results, Provide a business update And Host a Conference call 29.08.2025 / 07:00 CET/CEST
Basel, Switzerland. August 28, 2025, 7am CET.
BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company fo [ … ]
Wed, 27.08.2025
BioVersys AG
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland, August 27, 2025, 7am CET
Orphan designation is granted to drug candidates addressing life-threatening or chronically debilitating diseases affecting fewer than 5 in 10’000 EU residents
EMA orphan status provides key incentives, including reduced fees, research and c [ … ]
Wed, 02.07.2025
BioVersys AG
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland. July 2, 2025, 7am CEST.
The Global Research Collaboration is a research and exclusive license option agreement with Shionogi to jointly develop novel ansamycin leads from BioVersys’ BV500 program into clinical candidates
Shionogi gets access to BioVersys’ proprietary ansamycin [ … ]
Mon, 30.06.2025
BioVersys AG
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland. June 30, 2025, 7am CEST
BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant ("MDR") bacteria, today a [ … ]
Tue, 03.06.2025
BioVersys AG
Ad hoc announcement pursuant to Art. 53 LR
.awlist1_1748898862_836540 { list-style:none; counter-set:awlistcounter24_0 }
.awlist1_1748898862_836540 > li:before { content:counter(awlistcounter24_0) '.'; counter-increment:awlistcounter24_0 }
.awlist2_1748898862_836540 { list-style:none; counter-set:awlistcounter24_1 }
.awlist2_1748898862_ [ … ]
Mon, 28.04.2025
BioVersys AG
BioVersys AG
/ Key word(s): Conference
BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter on May 7, 2025 28.04.2025 / 07:00 CET/CEST
Basel, Switzerland. April 28, 2025, 7am CET
Event titled “BV100 Shows Survival Benefit in Pha [ … ]
Tue, 08.04.2025
BioVersys AG
BioVersys AG
/ Key word(s): Conference
BIOVERSYS TO PRESENT BV100 PHASE 2 DATA AT 35TH ESCMID GLOBAL 2025 08.04.2025 / 07:00 CET/CEST
Basel, Switzerland. April 08, 2025, 7am CEST.
Oral presentation on April 13, 2025, highlighting positive BV100 Phase 2 VABP trial read-out with excellent efficacy and safety data
Complementary [ … ]
Mon, 31.03.2025
BioVersys AG
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland. March 31, 2025, 7am CET
Important patent around BioVersys’ BV100 drug candidate has been granted, protecting the proprietary rifabutin IV formulation technology in China
BV100 patents have now been granted in over 25 countries, including in US, Europe, UK and China
BioVersys AG (SIX [ … ]
Wed, 26.03.2025
BioVersys AG
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland. March 26, 2025, 7am CET
BV100: Positive Phase 2 VABP trial read-out with excellent safety and efficacy data
Alpibectir: Phase 2a EBA trial delivered very strong proof of concept
Preclinical candidates from BioVersys’ two proprietary platforms continue to progress
Full Year 2024 oper [ … ]
